Combined surgical and molecular therapy: The gastrointestinal stromal tumor model

Annals of Surgery

Volumn 244, Issue 2, 2006, Pages 176-184

  Gold, Jason S ^a   DeMatteo, Ronald P ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; DOXORUBICIN; EVEROLIMUS; IMATINIB; MIDOSTAURIN; N (3,3 DIMETHYL 6 INDOLINYL) 2 (4 PYRIDINYLMETHYLAMINO)NICOTINAMIDE; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; STEM CELL FACTOR; SUNITINIB; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ARTIFICIAL EMBOLISM; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER RECURRENCE; CANCER RESEARCH; CANCER RESISTANCE; CANCER RISK; CANCER SURGERY; CANCER THERAPY; CARCINOGENESIS; CHRONIC MYELOID LEUKEMIA; CLINICAL ASSESSMENT; CLINICAL OBSERVATION; CLINICAL TRIAL; DIARRHEA; DOSE CALCULATION; DRUG EFFECT; DRUG EFFICACY; DRUG ERUPTION; DRUG MECHANISM; DRUG RESEARCH; DRUG SAFETY; DRUG TARGETING; DRUG WITHDRAWAL; FATIGUE; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; HEPATIC ARTERY; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; LIVER RESECTION; MEDICAL LITERATURE; METASTASIS; MOLECULAR DYNAMICS; MULTIMODALITY CANCER THERAPY; MUSCLE CRAMP; NAUSEA; PATHOLOGY; PATIENT CARE; PERIORBITAL EDEMA; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; RARE DISEASE; RECURRENT CANCER; REVIEW; SMALL INTESTINE; SOLID TUMOR; STOMACH; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT PLANNING; TREATMENT RESPONSE; TUMOR LOCALIZATION; TUMOR MODEL;

ANTINEOPLASTIC AGENTS; GASTROINTESTINAL NEOPLASMS; GASTROINTESTINAL STROMAL TUMORS; HUMANS; NEOADJUVANT THERAPY; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES;

EID: 33748101399     PISSN: 00034932     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.sla.0000218080.94145.cf     Document Type: Review

References (61)

1. Allander SV, Nupponen NN, Ringner M, et al. Gastrointestinal stromal tumors with KIT mutations exhibit a remarkably homogeneous gene expression profile. Cancer Res. 2001;61:8624-8628.
2. Nielsen TO, West RB, Linn SC, et al. Molecular characterisation of soft tissue tumours: a gene expression study. Lancet. 2002;359:1301-1307.
3. Segal NH, Pavlidis P, Antonescu CR, et al. Classification and subtype prediction of adult soft tissue sarcoma by functional genomics. Am J Pathol. 2003;163:691-700.
4. DeMatteo RP, Lewis JJ, Leung D, et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg. 2000;231:51-58.
5. Pierie J-PEN, Choudry U, Muzikansky A, et al. The effect of surgery and grade on outcome of gastrointestinal stromal tumors. Arch Surg. 2001;136:383-389.
6. Singer S, Rubin BP, Lux ML, et al. Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors. J Clin Oncol. 2002;20:3898-3905.
7. Fujimoto Y, Nakanishi Y, Yoshimura K, et al. Clinicopathologic study of primary malignant gastrointestinal stromal tumor of the stomach, with special reference to prognostic factors: analysis of results in 140 surgically resected patients. Gastric Cancer. 2003;6:39-48.
8. Langer C, Gunawan B, Schuler P, et al. Prognostic factors influencing surgical management and outcome of gastrointestinal stromal tumours. Br J Surg. 2003;90:332-339.
9. Nishida T, Hirota S, Taniguchi M, et al. Familial gastrointestinal stromal tumours with germline mutation of the KIT gene. Nat Genet. 1998;19:323-324.
10. Chompret A, Kannengiesser C, Barrois M, et al. PDGFRA germline mutation in a family with multiple cases of gastrointestinal stromal tumor. Gastroenterology. 2004;126:318-321.
11. Thomas RM, Sobin LH. Gastrointestinal cancer. Cancer. 1995;75(suppl 1):154-70.
12. Kindblom LG. Gastrointestinal Stromal Tumors; Diagnosis, Epidemiology, Prognosis. ASCO Annual Meeting, Chicago, 2003.
13. Emory TS, Sobin LH, Lukes L, et al. Prognosis of gastrointestinal smooth-muscle (stromal) tumors: dependence on anatomic site. Am J Surg Pathol. 1999;23:82-87.
14. Dematteo RPRP, Maki RGRG, Antonescu CC, et al. Targeted molecular therapy for cancer: the application of STI571 to gastrointestinal stromal tumor. Curr Probl Surg. 2003;40:144-193.
15. Fletcher CDM, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol. 2002;33:459-465.
16. Medeiros F, Corless CL, Duensing A, et al. KIT-negative gastrointestinal stromal tumors: proof of concept and therapeutic implications. Am J Surg Pathol. 2004;28:889-894.
17. Tzen CY, Mau BL. Analysis of CD117-negative gastrointestinal stromal tumors. World J Gastroenterol. 2005;11:1052-1055.
18. Crosby JA, Catton CN, Davis A, et al. Malignant gastrointestinal stromal tumors of the small intestine: a review of 50 cases from a prospective database. Ann Surg Oncol. 2001;8:50-59.
19. Miettinen M, El-Rifai WE, Leslie HS, et al. Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: a review. Hum Pathol. 2002;33:478-483.
20. Subramanian S, West RB, Corless CL, et al. Gastrointestinal stromal tumors (GISTs) with KIT and PDGFRA mutations have distinct gene expression profiles. Oncogene. 2004;23:7780-7790.
21. Lasota J, Dansonka-Mieszkowska A, Sobin LH, et al. A great majority of GISTs with PDGFRA mutations represent gastric tumors of low or no malignant potential. Lab Invest. 2004;84:874-883.
22. Taniguchi M, Nishida T, Hirota S, et al. Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors. Cancer Res. 1999;59:4297-4300.
23. Kim TW, Lee H, Kang Y-K, et al. Prognostic significance of c-kit mutation in localized gastrointestinal stromal tumors. Clin Cancer Res. 2004;10:3076-3081.
24. Demetri GD, Benjamin R, Blanke CD, et al. Optimal management of patients with gastrointestinal stromal tumors (GIST): expansion and update of NCCN Clinical Practice Guidelines. J Comprehensive Cancer Network. 2004;2(suppl 1):1-26.
25. Blay JY, Bonvalot S, Casali P, et al. Consensus meeting for the management of gastrointestinal stromal tumors: Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO. Ann Oncol. 2005;16:566-578.
26. DeMatteo RP, Shah A, Fong Y, et al. Results of hepatic resection for sarcoma metastatic to liver. Ann Surg. 2001;234:540-547; discussion 547-548.
27. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 1998;279:577-580.
28. Antonescu CR, Viale A, Sarran L, et al. Gene expression in gastrointestinal stromal tumors is distinguished by KIT genotype and anatomic site. Clin Cancer Res. 2004;10:3282-3290.
29. Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol. 2003;21:4342-4349.
30. Sommer G, Agosti V, Ehlers I, et al. Gastrointestinal stromal tumors in a mouse model by targeted mutation of the Kit receptor tyrosine kinase. Proc Natl Acad Sci USA. 2003;100:6706-6711.
31. Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996;2:561-566.
32. Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med. 2001;344:1052-1056.
33. van Oosterom AT, Judson I, Verweij J, et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet. 2001;358:1421-1423.
34. Heinrich MC, Rubin BP, Longley BJ, et al. Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterations. Hum Pathol. 2002;33:484-495.
35. van Oosterom AT, Judson IR, Verweij J, et al. Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer. 2002;38(suppl 5):83-87.
36. Benjamin RS, Rankin C, Fletcher C, et al. Phase III dose-randomized study of imatinib mesylate (STI571) for GIST: Intergroup S0033 early results [Abstr 3271]. Proc Am Soc Clin Oncol. 2003;22:814.
37. Verweij PJ, Casali PG, Zalcberg PJ, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet. 2004;364:1127-1134.
38. Blanke C, Joensuu H, Demetri G, et al. Long-term follow up of advanced gastrointestinal stromal tumor (GIST) patients treated with imatinib mesylate. 2004 Gastrointestinal Cancers Symposium, San Francisco, 2004.
39. Mudan SS, Conlon KC, Woodruff JM, et al. Salvage surgery for patients with recurrent gastrointestinal sarcoma: prognostic factors to guide patient selection. Cancer. 2000;88:66-74.
40. Blackstein ME, Rankin C, Fletcher C, et al. Clinical benefit of Imatinib in patients (pts) with metastatic gastrointestinal stromal tumors (GIST) negative for the expression of CD117 in the S0033 trial. J Clin Oncol. 2005;23(16 suppl):9010.
41. Le Cesne A, Perol D, Ray-Coquard I, et al. Interruption of imatinib (IM) in GIST patients with advanced disease: updated results of the prospective French Sarcoma Group randomized phase III trial on survival and quality of life. J Clin Oncol. 2005;23(16 suppl):9031.
42. Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer. 1981;47:207-214.
43. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-216.
44. Choi H, Charnsangavej C, de Castro Faria S, et al. CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings. AJR Am J Roentgenol. 2004;183:1619-1628.
45. Goerres GW, Stupp R, Barghouth G, et al. The value of PET, CT and in-line PET/CT in patients with gastrointestinal stromal tumours: long-term outcome of treatment with imatinib mesylate. Eur J Nucl Med Mol Imaging. 2005;32:153-162.
46. Debiec-Rychter M, Dumez H, Judson I, et al. Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer. 2004;40:689-695.
47. Heinrich MC, Shoemaker JS, Corless CL, et al. Correlation of target kinase genotype with clinical activity of imatinib mesylate (IM) in patients with metastatic GI stromal tumors (GISTs) expressing KIT (KIT+). J Clin Oncol. 2005;23(16 suppl):7.
48. Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science. 2003;299:708-710.
49. Fletcher JA, Corless CL, Dimitrijevic S, et al. Mechanisms of resistance to imatinib mesylate (IM) in advanced gastrointestinal stromal tumor (GIST) [Abstr 3275]. Proc Am Soc Clin Oncol. 2003;22:815.
50. Chen LL, Trent JC, Wu EF, et al. A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors. Cancer Res. 2004;64:5913-5919.
51. Debiec-Rychter M, Cools J, Dumez H, et al. Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants. Gastroenterology. 2005;128:270-279.
52. Antonescu CR, Besmer P, Guo T, et al. Acquired resistance to Imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res. 2005;11:4182-4190.
53. Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 2001;293:876-880.
54. Shah NP, Nicoll JM, Nagar B, et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell. 2002;2:117-125.
55. Tamborini E, Bonadiman L, Greco A, et al. A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient. Gastroenterology. 2004;127:294-299.
56. Wardelmann E, Thomas N, Merkelbach-Bruse S, et al. Acquired resistance to imatinib in gastrointestinal stromal tumours caused by multiple KIT mutations. Lancet Oncol. 2005;6:249-251.
57. Demetri GD, Desai J, Fletcher JA, et al. SU11248, a multi-targeted tyrosine kinase inhibitor, can overcome imatinib (IM) resistance caused by diverse genomic mechanisms in patients with metastatic gastrointestinal stromal tumor (GIST). J Clin Oncol. 2004;22(14 suppl):3001.
58. Desai J, Maki R, Heinrich MC, et al. Activity and tolerability of the multi-targeted tyrosine kinase inhibitor SU011248 in patients with metastatic gastrointestinal stromal tumor (GIST) refractory to imatinib mesylate. 2004 Gastrointestinal Cancers Symposium, San Francisco, 2004.
59. Maki RG, Fletcher JA, Heinrich MC, et al. Results from a continuation trial of SU11248 in patients (pts) with imatinib (IM)-resistant gastrointestinal stromal tumor (GIST). J Clin Oncol. 2005;23(16 suppl):9011.
60. Demetri GD, van Oosterom AT, Blackstein M, et al. Phase 3, multicenter, randomized, double-blind, placebo-controlled trial of SU11248 in patients following failure of imatinib for metastatic GIST. J Clin Oncol. 2005;23(16 suppl):4000.
61. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347:472-480.